Status:
COMPLETED
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
Lead Sponsor:
AstraZeneca
Conditions:
Squamous Cell Cancer
Cancer of Head and Neck
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination
Eligibility Criteria
Inclusion
- Provision of written informed consent
- Patients with histologically proven primary SCCHN
- Aged 18 or over
Exclusion
- Patients eligible for surgery with curative intent
- Other co-existing malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
- Exclude UCNT
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00255476
Start Date
February 1 2004
End Date
July 1 2007
Last Update
April 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom